SRSF3 and gastric neoplasm: In vivo studies and patient sample analyses confirm elevated levels of DARPP-32, CD44E, and SRp20 in gastric tumors, suggesting that the DARPP-32-SRp20-CD44E pathway could be a viable therapeutic target.